Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus Nucleus, PML body Note=Recruited to PML body by PML. |
Domain |
PF13516 Leucine Rich repeat |
Function |
Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. No DNA binding of in vitro translated CIITA was detected. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter. Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Exhibits intrinsic GTP-stimulated acetyltransferase activity. Exhibits serine/threonine protein kinase activity: can phosphorylate the TFIID component TAF7, the RAP74 subunit of the general transcription factor TFIIF, histone H2B at 'Ser-37' and other histones (in vitro). |
Biological Process |
GO:0010712 regulation of collagen metabolic process GO:0010713 negative regulation of collagen metabolic process GO:0032963 collagen metabolic process GO:0032964 collagen biosynthetic process GO:0032965 regulation of collagen biosynthetic process GO:0032966 negative regulation of collagen biosynthetic process GO:0034341 response to interferon-gamma GO:0044236 multicellular organism metabolic process GO:0044246 regulation of multicellular organismal metabolic process GO:0044252 negative regulation of multicellular organismal metabolic process GO:0044259 multicellular organismal macromolecule metabolic process GO:0045341 MHC class I biosynthetic process GO:0045342 MHC class II biosynthetic process GO:0045343 regulation of MHC class I biosynthetic process GO:0045345 positive regulation of MHC class I biosynthetic process GO:0045346 regulation of MHC class II biosynthetic process GO:0045348 positive regulation of MHC class II biosynthetic process GO:0046677 response to antibiotic GO:0060333 interferon-gamma-mediated signaling pathway GO:0071346 cellular response to interferon-gamma |
Molecular Function |
GO:0003713 transcription coactivator activity GO:0005525 GTP binding GO:0008022 protein C-terminus binding GO:0008134 transcription factor binding GO:0016746 transferase activity, transferring acyl groups GO:0019001 guanyl nucleotide binding GO:0032561 guanyl ribonucleotide binding GO:0033613 activating transcription factor binding |
Cellular Component |
GO:0016604 nuclear body GO:0016605 PML body |
KEGG |
hsa04612 Antigen processing and presentation |
Reactome |
R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-913531: Interferon Signaling R-HSA-877300: Interferon gamma signaling |
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CIITA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CIITA and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CIITA in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CIITA in various data sets.
|
Points in the above scatter plot represent the mutation difference of CIITA in various data sets.
|
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CIITA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CIITA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CIITA. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CIITA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CIITA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CIITA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CIITA |
Name | class II, major histocompatibility complex, transactivator |
Aliases | NLRA; NLR family, acid domain containing; nucleotide-binding oligomerization domain, leucine rich repeat and ...... |
Chromosomal Location | 16p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CIITA collected from DrugBank database. |
There is no record. |